Repare Therapeutics Inc.
RPTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $53,477 | $51,133 | $131,830 | $7,600 |
| % Growth | 4.6% | -61.2% | 1,634.6% | – |
| Cost of Goods Sold | $13,378 | $13,239 | $116,722 | $87,854 |
| Gross Profit | $40,099 | $37,894 | $15,108 | -$80,254 |
| % Margin | 75% | 74.1% | 11.5% | -1,056% |
| R&D Expenses | $116,873 | $133,593 | $120,500 | $91,171 |
| G&A Expenses | $29,680 | $33,764 | $32,560 | $26,213 |
| SG&A Expenses | $32,218 | $33,764 | $34,904 | $28,406 |
| Sales & Mktg Exp. | $2,538 | $0 | $2,344 | $2,193 |
| Other Operating Expenses | -$15,469 | -$13,239 | -$120,500 | -$91,171 |
| Operating Expenses | $133,622 | $154,118 | $34,904 | $28,406 |
| Operating Income | -$93,523 | -$116,224 | -$19,796 | -$108,660 |
| % Margin | -174.9% | -227.3% | -15% | -1,429.7% |
| Other Income/Exp. Net | $10,274 | $13,045 | $5,896 | $74 |
| Pre-Tax Income | -$83,249 | -$103,179 | -$13,900 | -$108,586 |
| Tax Expense | $1,440 | -$9,383 | $15,147 | -$1,678 |
| Net Income | -$84,689 | -$93,796 | -$29,047 | -$106,908 |
| % Margin | -158.4% | -183.4% | -22% | -1,406.7% |
| EPS | -2 | -2.23 | -0.69 | -2.83 |
| % Growth | 10.3% | -223.2% | 75.6% | – |
| EPS Diluted | -2 | -2.23 | -0.69 | -2.83 |
| Weighted Avg Shares Out | 42,411 | 42,093 | 41,922 | 37,818 |
| Weighted Avg Shares Out Dil | 42,411 | 42,093 | 41,922 | 37,818 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,391 | $13,334 | $5,631 | $259 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,921 | $1,951 | $1,978 | $1,471 |
| EBITDA | -$90,223 | -$114,273 | -$17,818 | -$107,189 |
| % Margin | -168.7% | -223.5% | -13.5% | -1,410.4% |